New wrinkle treatment combo shows promise in early trial

NCT ID NCT06834789

Completed Symptom relief Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested whether a new drug called AGN-151586 can be safely combined with BOTOX to treat moderate to severe frown lines between the eyebrows. Researchers monitored 132 healthy adults for side effects and immune responses after a single treatment session. The goal was to check safety and see if the combination works better than BOTOX alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLABELLAR LINES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLABELLAR LINES

Contacts and locations

Locations

Austin Institute for Clinical Research - Pflugerville /ID# 270834

Pflugerville, Texas, 78660, United States
Eye Research Foundation /ID# 270827

Newport Beach, California, 92663, United States
Investigate MD /ID# 270771

Scottsdale, Arizona, 85260, United States
Marcus Facial Plastic Surgery /ID# 270770

Redondo Beach, California, 90277, United States
Skin Research Institute LLC /ID# 270831

Coral Gables, Florida, 33146-1837, United States
SkinDC /ID# 270932

Arlington, Virginia, 22209, United States
Skincare Physicians /ID# 271018

Chestnut Hill, Massachusetts, 02467, United States
Wilmington Dermatology Center /ID# 270828

Wilmington, North Carolina, 28403, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.